Founder Chris Gibson to exit Recursion Pharmaceuticals (NASDAQ: RXRX) board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Recursion Pharmaceuticals announced a planned board transition involving its founder and current Chair, Chris Gibson, Ph.D. On April 28, 2026 he informed the company that he will not stand for re-election as a Class II director at the 2026 Annual Meeting of Stockholders.
The filing states his decision is not due to any disagreement with the company on operations, policies, or practices. Dr. Gibson will continue serving as Chair of the Board and on its committees through the end of his current term and will remain involved as a strategic advisor thereafter, supporting leadership continuity.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
Annual Meeting of Stockholders, Regulation FD Disclosure, emerging growth company, forward-looking statements, +1 more
5 terms
Annual Meeting of Stockholders financial
"will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders"
Regulation FD Disclosure regulatory
"Item 7.01. Regulation FD Disclosure. On April 30, 2026, the Company issued a press release"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
forward-looking statements regulatory
"This press release contains forward-looking statements, including, without limitation, statements regarding Recursion’s future plans"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Class II Director financial
"will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
FAQ
What board change did Recursion Pharmaceuticals (RXRX) disclose in this 8-K?
Recursion disclosed that founder and Board Chair Chris Gibson, Ph.D., will not stand for re-election as a Class II director at the 2026 Annual Meeting, while continuing to serve as Chair until then and remaining involved as a strategic advisor afterward.
Did Chris Gibson resign immediately from the Recursion (RXRX) board?
No. Chris Gibson will complete his current term through the 2026 Annual Meeting of Stockholders. Until then, he will continue serving as Chair of the Board and on its committees, ensuring an orderly transition rather than an abrupt departure from governance roles.
Did Chris Gibson’s decision involve any disagreement with Recursion (RXRX)?
The filing states that Chris Gibson’s decision not to seek re-election did not result from any disagreement with Recursion on operations, policies, or practices. This language is intended to reassure investors that the transition is not driven by governance or strategic conflict.
What ongoing role will Chris Gibson have at Recursion (RXRX) after leaving the board?
After his current term ends, Chris Gibson will remain connected to Recursion as a strategic advisor. Company statements highlight his continued involvement in supporting leadership, reflecting a shift from formal board service to an advisory capacity rather than a complete separation.
How did Recursion (RXRX) communicate the board transition to the market?
Recursion furnished a press release as Exhibit 99.1 to the 8-K, describing the board transition. The company emphasized leadership continuity, Gibson’s ongoing advisory role, and its focus on advancing its internal and partnered pipeline and AI-powered drug discovery platform.